2. Search Result
Search Result
Results for "

clotting factor

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Inhibitory Antibodies

2

Natural
Products

2

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W040030
    Hematin

    		Cytochrome P450 Metabolic Disease Cancer
    Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .
    Hematin
  • HY-153480A
    ARC19499 sodium

    BAX499 sodium

    		 Factor Xa Factor VIIa Tissue Factor Pathway Inhibitor (TFPI) Others
    ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499 sodium
  • HY-B2172
    Vitamin K

    		Endogenous Metabolite Cardiovascular Disease Cancer
    Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
    Vitamin K
  • HY-14854
    Tecarfarin

    ATI-5923

    		 VKOR Cardiovascular Disease
    Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin has the antithrombotic activity .
    Tecarfarin
  • HY-153480
    ARC19499

    BAX499

    		 Factor Xa Factor VIIa Tissue Factor Pathway Inhibitor (TFPI) Others
    ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499
  • HY-147393
    Factor VII-IN-1

    		Ser/Thr Protease Cardiovascular Disease
    Factor VII-IN-1 (example 43) is a potent inhibitor of factor VII (FVII), with an IC50 of 1.1 μM. Factor VII-IN-1 shows anticoagulant properties .
    Factor VII-IN-1
  • HY-120491
    L 722151

    		Thrombin Cardiovascular Disease
    L 722151 is a competitive inhibitor for factor XIIIa with Ki of 49 µM. L 722151 accelerates tissue plasminogen activator-catalyzed clot dissolution, and exhibits antithrombotic efficacy .
    L 722151
  • HY-P991213
    Nonacog gamma

    		Factor XI Cardiovascular Disease
    Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .
    Nonacog gamma
  • HY-172231
    Hexolame

    		Estrogen Receptor/ERR Cardiovascular Disease
    Hexolame is an estrogen receptors agonist with dual anticoagulant and estrogenic properties. Hexolame binds to estrogen receptors to induce anticoagulant effects by modulating clotting factors or platelet activity. Hexolame is promising for research of prostatic cancer and prevention of thrombosis .
    Hexolame
  • HY-N13960
    Bacithrocin D

    Thiolstatin D

    		 Thrombin Factor Xa Cardiovascular Disease
    Bacithrocin D (Thiolstatin D) inhibits multiple proteases and can prolong the clotting time. Bacithrocin D has IC50 values of 124, 9, 0.85, and 0.01 μM for thrombin, factor Xa, trypsin, and papain, respectively .
    Bacithrocin D
  • HY-14854A
    Tecarfarin sodium

    ATI-5923 sodium

    		 VKOR Metabolic Disease
    Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin sodium has the antithrombotic activity .
    Tecarfarin sodium
  • HY-107966
    Heparin calcium (MW 15000-19000)

    Nadroparin calcium (MW 15000-19000)

    		 Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 15000-19000)
  • HY-107966A
    Heparin calcium (MW 3600-5000)

    Nadroparin calcium (MW 3600-5000)

    		 Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 3600-5000)
  • HY-117290
    BMS-962212

    		Factor Xa Cardiovascular Disease
    BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity .
    BMS-962212
  • HY-P991211
    Bemiltenase alfa

    		Factor XI Cardiovascular Disease
    Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .
    Bemiltenase alfa
  • HY-19517
    R1663

    		Endogenous Metabolite Cardiovascular Disease
    R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
    R1663
  • HY-50667R
    Apixaban (Standard)

    		Factor Xa Cardiovascular Disease Cancer
    Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban (Standard)
  • HY-50667S
    Apixaban-13C,d3

    BMS-562247-01-13C,d3

    		 Factor Xa Cardiovascular Disease
    Apixaban- 13C,d3 is a deuterium and 13C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .
    Apixaban-13C,d3
  • HY-113958
    Difethialone

    LM-2219

    		 VD/VDR Others
    Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone
  • HY-50667
    Apixaban
    10+ Cited Publications

    BMS-562247-01

    		 Factor Xa Cardiovascular Disease Cancer
    Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban
  • HY-113958R
    Difethialone (Standard)

    		TrxR Others
    Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone (Standard)
  • HY-14854S
    Tecarfarin-13C,d3

    ATI-5923-13C,d3

    		 Isotope-Labeled Compounds VKOR Cardiovascular Disease
    Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin has the antithrombotic activity .
    Tecarfarin-13C,d3
  • HY-B0385
    Gabexate mesylate
    4 Publications Verification

    FOY

    		 Proteasome Factor Xa Inflammation/Immunology
    Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
    Gabexate mesylate
  • HY-B0385R
    Gabexate (mesylate) (Standard)

    		Proteasome Factor Xa Inflammation/Immunology
    Gabexate (mesylate) (Standard) is the analytical standard of Gabexate (mesylate). This product is intended for research and analytical applications. Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
    Gabexate (mesylate) (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: